文献速递其他结缔组织病

演变中的治疗模式对系统性硬化症相关间质性肺病进展的影响:基于欧洲硬皮病试验与研究数据库

Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database.
PubMed 文献 · Arthritis Rheumatol · 2026-03-29

该研究基于欧洲硬皮病试验与研究数据库,纳入1409例符合2013年ACR/EULAR标准且高分辨率CT确认ILD的系统性硬化症患者,分析四个时间段治疗趋势及IST和抗纤维化治疗对ILD进展的影响。结果显示IST使用从13.6%增至57.4%,霉酚酸酯成为最常用IST,联合治疗从17.9%升至26.9%,ILD进展率从21.3%降至12.1%。

要点

  • IST使用显著增加,霉酚酸酯成为最常用药物。
  • 联合治疗比例上升,ILD进展率下降。
  • 2017年后队列中肌炎与治疗启动相关,关节炎与换药相关。

核心结论

  • 临床实践显著演变,但疾病持续进展强调需要更有效的治疗策略。

研究设计与样本

  • 基于欧洲硬皮病试验与研究数据库的队列研究,纳入1409例符合2013年ACR/EULAR标准且HRCT确认ILD的系统性硬化症患者,按四个时间段分组分析。

主要发现

  • 首次评估时IST使用从≤2006年的13.6%显著增至≥2017年的57.4%(P < 0.001)。
  • 霉酚酸酯成为最常用IST,使用比例从7%增至57%(P < 0.001)。
  • 联合治疗从17.9%升至26.9%(P < 0.001),ILD进展率从21.3%(2007-2011)降至12.1%(≥2017)(P < 0.001)。
  • 在2017及以后队列中,较短病程(OR 0.991,95%CI 0.987-0.996;P < 0.001)和肌炎(OR 9.9,95%CI 1.94-51.76;P = 0.006)与治疗启动相关。
  • 换药在较高改良Rodnan皮肤评分(OR 1.03,95%CI 1.00-1.06;P = 0.035)和关节炎(OR 3.03,95%CI 1.55-5.94;P = 0.001)患者中更高;联合治疗与较年轻年龄、较高呼吸困难分级和关节炎相关。

关键数值与推荐

  • ILD进展定义为12±3个月内预测用力肺活量百分比下降≥5%或预测一氧化碳弥散量百分比下降≥10%。

临床怎么用

  • 临床实践中IST和联合治疗使用增加与ILD进展率下降相关,但部分患者仍进展,需更有效治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The treatment landscape for systemic sclerosis-associated interstitial lung disease (SSc-ILD) has evolved with increasingly available immunosuppressive therapies (ISTs) and antifibrotic treatments. However, their real-world use remains unclear. The objective of this study was to analyze treatment trends and the effect of IST and antifibrotic treatments on ILD progression using the European Scleroderma Trials and Research database. METHODS: We included patients with SSc-ILD meeting the 2013 American College of Rheumatology/EULAR criteria with high-resolution computed tomography-confirmed ILD, pulmonary function, and therapy data, grouped into four time periods (≤2006, 2007-2011, 2012-2016, and ≥2017). We analyzed IST initiation, switching, discontinuation, and combination therapy. ILD progression was defined as a decline in the percentage of predicted forced vital capacity of 5% or greater or the percentage of predicted diffusing capacity of the lungs for carbon monoxide of 10% or greater over 12 ± 3 months. RESULTS: Among 1,409 patients, IST use at first evaluation increased significantly from 13.6% (≤2006) to 57.4% (≥2017) (P < 0.001). Mycophenolate mofetil emerged as the most prescribed IST (7% to 57%) (P < 0.001). Combination therapy rose from 17.9% to 26.9% (P < 0.001), whereas ILD progression rates declined from 21.3% (2007-2011) to 12.1% (≥2017) (P < 0.001). In the 2017 and later cohort, logistic regression showed shorter disease duration (odds ratio [OR] 0.991, 95% confidence interval [CI] 0.987-0.996; P < 0.001) and myositis (OR 9.9, 95% CI 1.94-51.76; P = 0.006) were associated with therapy initiation, whereas switching was higher in patients with a higher modified Rodnan skin score (OR 1.03, 95% CI 1.00-1.06; P = 0.035) and in patients with arthritis (OR 3.03, 95% CI 1.55-5.94; P = 0.001). Last, combination therapy was associated with younger age, higher dyspnea class, and arthritis. CONCLUSION: Our findings reveal a significant evolution in clinical practice. However, continued disease progression emphasizes the need for more effective therapeutic approaches.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Campochiaro C, Truchetet ME, Vonk M, et al. Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database. Arthritis Rheumatol. 2026. PMID: 41568546. doi:10.1002/art.70043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。